Skip to main content
. 2021 Mar 19;16(16):1318–1325. doi: 10.4244/EIJ-D-19-00296

Table 1. Baseline patient characteristics.

Variables Total stent length (mm) Overall population p-value
≤40 (N=8,035) >40 (N=1,182) (N=9,217)
Age, years 63.3±11.1 65.5±10.8 63.6±11.1 <0.001
Gender, male 5,631 (70.1%) 839 (71.0%) 6,470 (70.2%) 0.527
Diabetes mellitus 2,699 (33.6%) 463 (39.2%) 3,162 (34.3%) <0.001
Hypertension 4,814 (59.9%) 751 (63.5%) 5,565 (60.4%) 0.017
Dyslipidaemia 3,274 (40.7%) 486 (41.1%) 3,760 (40.8%) 0.809
PVD 141 (1.8%) 29 (2.5%) 170 (1.8%) 0.096
CKD 2,670 (35.4%) 453 (40.7%) 3,123 (36.0%) <0.001
Current smoking 2,426 (30.2%) 307 (26.0%) 2,733 (29.7%) 0.003
Previous PCI 1,375 (17.1%) 173 (14.6%) 1,548 (16.8%) 0.033
Previous CABG 160 (2.0%) 35 (3.0%) 195 (2.1%) 0.031
Previous MI 476 (5.9%) 72 (6.1%) 548 (5.9%) 0.820
Previous CHF 162 (2.0%) 38 (3.2%) 200 (2.2%) 0.008
Previous CVA 589 (7.3%) 112 (9.5%) 701 (7.6%) 0.009
Diagnosis
Stable angina 2,622 (32.6%) 396 (33.5%) 3,018 (32.7%)
Unstable angina 2,689 (33.5%) 370 (31.3%) 3,059 (33.2%)
NSTEMI 1,078 (13.4%) 166 (14.0%) 1,244 (13.5%)
STEMI 1,300 (16.2%) 177 (15.0%) 1,477 (16.0%)
LVEF (%) 58.5±14.2 56.5±11.9 58.2±13.9 <0.001
LV dysfunction (EF <40%) 1,659 (20.6%) 243 (20.6%) 1,902 (20.6%) 0.944
Medications
Aspirin 7,969 (99.3%) 1,171 (99.2%) 9,140 (99.3%) 0.804
Clopidogrel 7,845 (97.8%) 1,161 (98.4%) 9,006 (97.8%) 0.170
DAPT 7,952 (99.0%) 1,170 (99.0%) 9,122 (99.0%) 0.955
Statin 7,070 (88.0%) 1,012 (85.6%) 8,082 (87.7%) 0.020
ACE inhibitors 2,579 (32.1%) 355 (30.0%) 2,394 (31.8%) 0.155
ARBs 2,540 (31.6%) 424 (35.9%) 2,964 (32.2%) 0.003
Beta-blockers 4,973 (61.9%) 772 (65.3%) 5,745 (62.3%) 0.023
CCB 2,035 (25.3%) 301 (25.5%) 2,336 (25.3%) 0.919
Warfarin 158 (2.0%) 28 (2.4%) 186 (2.0%) 0.358
Continuous variables expressed as mean±SD. ACE: angiotensin-converting enzyme; ARB: aldosterone receptor blocker; CABG: coronary artery bypass graft; CCB: calcium channel blocker; CHF: congestive heart failure; CKD: chronic kidney disease; CVA: cerebrovascular accident; DAPT: dual antiplatelet therapy; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; PVD: peripheral vascular disease; STEMI: ST-elevation myocardial infarction